- Vaccitech plc (NASDAQ:VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies.
- In the VTP-300 monotherapy group, meaningful and durable reductions of HBsAg were seen in all three patients with baseline HBsAg under 50 IU/mL.
- Related: Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial.
- HBsAg is a hallmark of chronic hepatitis B virus (HBV) infection.
- These three patients had 0.7, 0.7, and 1.4 log10 declines two months after the last VTP-300 and persisted in all three patients at their latest follow-up five or eight months after the last VTP-300.
- For the first eight patients who received VTP-300 in combination with a single low dose of nivolumab at the time of the booster dose, the mean reduction in HBsAg was over 1 log10 at six months and persisted with a mean decline of 1.15 log10 at eight months after the last dose of VTP-300.
- One patient developed a non-detectable HBsAg level, which continued eight months after the last dose of VTP-300.
- Enrollment in the HBV002 study is complete, with 55 patients enrolled.
- Updated interim analysis for all patients at the six-month follow-up timepoint is expected at the end of 2022.
- Price Action: VACC shares are up 21.70% at $5.55 during the market session on the last check Wednesday.
